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Background: Acute kidney injury (AKI) after surgery is associated with increased mortality and healthcare costs.
Fenoldopam is a selective dopamine-1 receptor agonist with renoprotective properties. We conducted a systematic
review and meta-analysis of randomised controlled trials comparing fenoldopam with placebo to prevent AKI after
major surgery.
Methods: We searched EMBASE, PubMed, meta-Register of randomised controlled trials and Cochrane CENTRAL
databases for trials comparing fenoldopam with placebo in patients undergoing major surgery. The primary
outcome was incidence of new AKI. Secondary outcomes were requirement for renal replacement therapy and
hospital mortality.
Results: Eighty-three publications were screened; 23 studies underwent full data extraction and scoring. Six trials
were suitable for inclusion in the data synthesis (total of 507 subjects undergoing cardiovascular surgery, partial
nephrectomy, liver transplant surgery). Five studies were rated at high risk of bias. Data on post-operative incidence
of AKI were available in five of the six trials (total of 471 patients) but definitions of AKI varied between studies. Of
the 238 patients receiving fenoldopam, 45 (18.9 %) developed AKI compared to 62 (26.6 %) of the 233 patients
who received placebo (p = 0.004, I2 = 0 %; random-effects model odds ratio 0.46, 95 % confidence interval
0.27–0.79). In patients treated with fenoldopam, there was no difference in renal replacement therapy
(n = 478; p = 0.11, I2 = 47 %; fixed-effect model odds ratio 0.27, 95 % confidence interval 0.06–1.19) or
hospital mortality (p = 0.60, I2 = 0 %; fixed-effect model odds ratio 1.0, 95 % confidence interval 0.14–7.37).
Conclusions: In this analysis, peri-operative treatment with fenoldopam was associated with a significant
reduction in post-operative AKI but it had no impact on renal replacement therapy or hospital mortality.
Equipoise remains for further large trials in this area since the studies were conducted in three types of
surgery, the majority of studies were rated at high risk of bias and the criteria for AKI varied between trials.
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Acute kidney injury (AKI) is an important complication
of high-risk surgery and is associated with increased
morbidity, mortality and healthcare costs [1–3]. Current
management strategies are largely preventative and
consist of avoidance of nephrotoxins, optimisation of
haemodynamics (including arterial pressure) and correction* Correspondence: Marlies.Ostermann@gstt.nhs.uk
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(http://creativecommons.org/publicdomain/zeof volume depletion. At present there are no therapeutic
agents that have demonstrated efficacy in preventing or
treating post-operative AKI.
Fenoldopam is a short-acting dopamine-1 receptor
agonist, licensed for the treatment of hypertension. It
decreases systemic vascular resistance while simultan-
eously increasing renal blood flow in patients with nor-
mal renal function and those with chronic kidney
disease (CKD) [4]. It has been investigated in off-label
studies as a potential agent to protect renal function
during the peri-operative period [5, 6]. In contrast tois distributed under the terms of the Creative Commons Attribution 4.0
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from experimental AKI models suggest that it also
has anti-inflammatory effects independent of its vaso-
dilatory action [7].
At least three meta-analyses have suggested that fenol-
dopam may reduce the incidence of AKI, reduce the re-
quirement for renal replacement therapy (RRT), and
reduce mortality during critical illness and in patients
undergoing cardiovascular interventions [8–10]. How-
ever, some of the studies included in these reviews were
either non-randomised, studies with an active compara-
tor, or trials performed in non-surgical patients.
Guidance on the role of fenoldopam in surgical and
critically ill patients is conflicting. In 2010, the European
Society of Intensive Care Medicine Working Group for
Nephrology published recommendations for the preven-
tion of AKI and suggested that the prophylactic use of
fenoldopam should be considered in patients at high risk
of AKI undergoing cardiovascular surgery [11]. Two
years later, the Kidney Disease Improving Global Out-
comes (KDIGO) expert committee released a new guide-
line and advised against the use of fenoldopam to
prevent or treat AKI in any context [12]. New data pro-
duced in 2010–2012 may have contributed to the change
in guidance.
Our aim was to review the existing data for fenoldo-
pam as a renoprotective agent in the peri-operative set-
ting and to perform a meta-analysis and systematic
review of all existing randomised controlled trials (RCTs)
comparing fenoldopam versus placebo in adult patients
undergoing any type of major surgery.
Methods
Search strategy
We searched EMBASE, PubMed, meta-Register of RCTs
(mRCT) and Cochrane CENTRAL databases using the
following pre-agreed search strategy: (fenoldopam OR
Corlopam) [tiab] AND rand*[tiab]. The search was
limited to RCTs in adult subjects. The bibliographies of
evaluable studies and other selected papers were hand
searched. Authors of published studies were also con-
tacted for more data as needed. Experts were contacted
and asked if they were aware of other studies not identi-
fied by our search strategy. Two authors (VK and RJP)
performed the literature search independently. Any dis-
parities were resolved by the consensus of all authors.
The search strategy and analysis were performed as per
the Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) statement 2009 [13].
Study selection
Two investigators (VK and RJP) independently examined
the abstracts of studies identified by the literature
search. The following criteria were used for inclusion inthe analysis: RCTs (blinded or unblinded) published be-
tween 1970 and 2015; trials comparing fenoldopam ver-
sus placebo for prevention of AKI; inclusion of patients
undergoing major surgery (elective or emergency); and
complete data available on any of the outcomes (Table 1).
The exclusion criteria were: duplicate publications;
studies not published in English; crossover studies;
non-human experimental studies; or lack of complete
or sufficient data to perform a meta-analysis of tar-
geted outcomes. Two investigators (MAG and MO)
then independently reviewed the full studies and
assessed compliance with the pre-agreed selection cri-
teria. Any disagreements were reviewed and resolved
by a third author (PMH).
The Cochrane Collaboration Risk of Bias tool was used
to assess the internal validity of included trials [14]. This
tool consists of six domains (allocation concealment,
random sequence generation, blinding, selective out-
come reporting, incomplete outcome data, and other
sources of bias). Each domain is rated low risk, unclear
risk, or high risk. If one or more individual domains
were considered as having a high risk of bias, the overall
score was assessed as having a high risk of bias. The
overall risk of bias was rated low only if all components
were assessed as having a low risk of bias.
Data extraction
Two investigators (PMH and MO) independently ex-
tracted the following information from each eligible art-
icle: study design (including patient selection and
treatment allocation), population, clinical setting, dosage
and duration of fenoldopam treatment, incidence of new
AKI, requirement for RRT, hospital mortality and re-
ported complications. If the necessary data could not be
extracted from the publication, the original authors were
contacted.
Outcomes
The primary outcome was incidence of new AKI (as
defined by the author). Secondary outcomes were
requirement for RRT and hospital mortality. If data
on mortality was not reported, data on AKI or RRT
were used; conversely, if only data on mortality were
available then this was used. A priori, a decision was
made to carry out a subgroup analysis on patients
undergoing cardiac surgery.
Statistical analysis
Statistical analysis was performed using Review Manager
(RevMan) v5.3, software used for preparing and main-
taining Cochrane Reviews. Between-study statistical het-
erogeneity was assessed by χ2 test and I2 test; values of
the index of 25, 50, and 75 % indicated the presence of
low, moderate, and high between-trial heterogeneity,
Table 1 Specification of the research question applying a PICO (population, intervention, comparison and outcome) model
Population Intervention Comparison Outcomes
Adult patients (≥18 years) undergoing
any type of major surgery
Treatment with fenoldopam in
the peri-operative period
Placebo Incidence of AKI Requirement for RRT
post-operatively Hospital mortality Side
effects (hypotension, need for
catecholamine treatment)
AKI acute kidney injury, RRT renal replacement therapy
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statistical significance of heterogeneity. The funnel plot
method was used to estimate potential publication bias
for any of the outcomes, either primary or secondary.
Dichotomous outcomes were expressed as a difference
of proportions (odds ratio (OR) with 95 % confidence
interval (CI)). If no significant heterogeneity was
noted, the fixed-effect model (FEM) analysis using the
Mantel-Haenszel method was performed. Otherwise,
the Simonian-Laird method was used to present the
results of the random-effects model (REM) analysis.
Results
Study selection
Figure 1 outlines the process for literature searching and
study selection. Eighty-three non-duplicate publications
were screened; 23 studies underwent full data extraction
and scoring. Six trials were suitable for inclusion in the
data synthesis (total of 507 subjects) (Table 2). Five trials
were rated at high risk of bias (Table 3).
Characteristics of included studies
Three of the six included trials were performed in
patients undergoing cardiac surgery [15–17]. The
remaining three studies were undertaken in patients
having aortic surgery [5], transplant surgery [18] or
a partial nephrectomy [19] (Table 2). Funnel plot of stud-
ies used in the primary outcome analysis indicated no evi-
dence of publication bias (Additional file 1).
Primary outcome
Data on post-operative incidence of new AKI were
available in five of the six trials included in the ana-
lysis (total of 471 patients). In one study no patient
developed AKI [5]. Significant reduction in AKI was
observed in patients receiving fenoldopam (Fig. 2).
Of 238 patients receiving fenoldopam, 45 (18.9 %)
developed AKI compared to 62 (26.6 %) of 233 pa-
tients who received placebo (p = 0.004, I2 = 0 %; REM
OR 0.46, 95 % CI 0.27–0.79). Three of these studies
(n = 304) were performed in cardiac surgery patients
[15–17]. When restricted to this cohort, significant
reduction in author-defined AKI was also found be-
tween the group receiving fenoldopam and the con-
trol group (p = 0.003, I2 = 0 %; FEM OR 0.34, 95 %
CI 0.16–0.69) (Additional file 2).Secondary outcomes
Data on new requirement for RRT in the post-operative
period were available in five of the six RCTs (total of 478
patients) [15–19]. Of 241 patients in the fenoldopam
group, 2 (0.8 %) were treated with RRT post-operatively
compared to 12 (4.5 %) of the 237 patients treated
with placebo. The reduction in incidence of the need
for RRT reported in the treatment arm was not sig-
nificant (p = 0.11, I2 = 47 %; FEM OR 0.27, 95 % CI
0.06–1.19) (Additional file 3).
Hospital mortality data were included in only two of
the six included RCTs, a total of 130 patients [15, 19].
Of the 65 patients receiving fenoldopam, 2 (3.1 %) died
compared to 2 (3.1 %) of 65 patients receiving placebo.
There was no difference in hospital mortality between
the fenoldopam and placebo group (p = 0.60, I2 = 0 %;
FEM OR 1.0, 95 % CI 0.14–7.37) (Fig. 3).
Discussion
The main finding of this analysis is that peri-operative
administration of fenoldopam to patients undergoing
cardiovascular surgery, partial nephrectomy or liver
transplant surgery significantly reduced the development
of AKI but did not significantly alter the requirement for
RRT or hospital mortality. Whether the conclusions can
be translated to other types of major surgery is unclear.
AKI is common in hospitalised patients, and influ-
ences both short- and long-term mortality. The recent
multi-national Acute Kidney Injury – Epidemiologic
Prospective Investigation (AKI-EPI) study demonstrated
that AKI occurred in more than half of intensive care
unit (ICU) patients (57 %) [20]. Amongst patients admit-
ted after surgery, 53 % developed post-operative AKI. A
study in patients undergoing cardiac surgery showed
that those who developed AKI post-operatively had a
significantly increased risk of dying for up to 10 years
after surgery, even if renal function had recovered at the
time of hospital discharge [21]. Similar data have also
been reported for patients undergoing other major surgi-
cal procedures [22]. Hence, strategies to reduce or miti-
gate the incidence of peri-operative AKI are of high
interest to clinicians.
The exact pathophysiology of AKI is not fully under-
stood but includes haemodynamic factors, dysregulation
of the renal microcirculation, inflammatory processes,
mitochondrial dysfunction and bio-energetic disturbance,
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Fig. 1 PRISMA flow diagram detailing search strategy and identification of studies used in data synthesis. AKI acute kidney injury, RRT renal
replacement therapy, mRCT metaRegister of Controlled Trials
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fusion is an important risk factor for AKI following sur-
gery, especially in combination with hypovolaemia [23]. It
has been hypothesised that fenoldopam may be able to
potentially reverse renal hypoperfusion, and hence prevent
or resolve AKI. In addition, fenoldopam may also have
anti-inflammatory effects independent of its vasodilatory
action [7].
Landoni et al. conducted three separate meta-analyses
exploring the role of fenoldopam [8–10]. The first meta-
analysis focussed on the effect of fenoldopam in critically
patients who had or were at risk of AKI [8]. Sixteen
RCTs were included (total of 1290 patients). The analysisconcluded that fenoldopam significantly reduced the de-
velopment of AKI, need for RRT, length of stay (LOS) in
ICU and hospital, and mortality. However, the analysis
was limited by the inclusion of both surgical and non-
surgical critically ill patients (i.e. sepsis), only 10 of the
included studies were placebo-controlled, most included
studies were of low quality, and the indications for start-
ing RRT were non-uniform between studies. Subse-
quently, they performed another meta-analysis with
focus on studies in patients who underwent cardiovascu-
lar surgery [9]. They concluded that fenoldopam signifi-
cantly reduced the need for RRT and was associated
with a lower in-hospital mortality. Of note, of the 13
Table 2 Summary of included studies
Author Time of study Type of surgery Number of
patients (F/P)
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Fig. 2 Forest plot of incidence of new acute kidney injury (as defined by authors). CI confidence interval, M-H Mantel-Haenszel
Gillies et al. Critical Care  (2015) 19:449 Page 7 of 9studies included in this meta-analysis, only nine were
randomised, and of these only four were placebo-
controlled. However, a post-hoc subgroup analysis of
just the RCTs confirmed the beneficial effects of fenol-
dopam. Finally, the same authors completed a third
meta-analysis where only placebo-controlled RCTs of
fenoldopam in cardiac surgery patients were included
[10]. Whilst there was a significant reduction in the de-
velopment of AKI, fenoldopam did not have a statisti-
cally significant effect on RRT, or hospital and ICU LOS.
Landoni and colleagues also conducted a multi-centre,
double-blind, placebo-controlled RCT to determine
whether fenoldopam reduced the need for RRT in critic-
ally ill cardiac surgery patients with AKI [24]. There was
no difference in RRT, ICU LOS, or mortality but a
higher incidence of hypotension in patients receiving
fenoldopam. While this is the largest study on the
subject till date (667 patients overall), it had several
limitations. The study was stopped early due to futil-
ity resulting in recruitment of only 667 patients in-
stead of the planned 1000 patients. AKI was defined
as per Risk–Injury–Failure–Loss–End-stage renal dis-
ease (RIFLE) classification but the criteria for initiat-
ing RRT were not pre-defined and left to the
judgement of the treating clinicians.
To the best of our knowledge, our study is the only
meta-analysis of fenoldopam use in the wider surgical
population. Strengths of our study were that robust
methodology was employed with an a priori analysis
plan and only studies involving subjects undergoingFig. 3 Forest plot for hospital mortality. CI confidence interval, M-H Mantelsurgery were included. All studies included were RCTs
published in peer-reviewed journals. There was little
statistical evidence of significant heterogeneity between
studies; heterogeneity was absent in the primary outcome
and in the secondary outcome of hospital mortality.
Moderate heterogeneity was detected in the secondary
outcome of new requirement for RRT.
However, in common with many meta-analyses, our
study did have several potential sources of bias. The defin-
ition of AKI was not uniform between studies. In fact, all
studies used different criteria for AKI as demonstrated in
Table 2. Some investigators used very conservative criteria
(e.g. peak creatinine >2 mg/dL (196 μmol/L)). None of the
studies had pre-defined criteria for RRT. It is important to
emphasize that our results have to be weighted on this
limitation. It is certainly possible that different rates of
AKI may have been observed if the authors had used
current consensus criteria which define AKI by a rise in
serum creatinine >26.4 μmol/L in 48 hours or less, or a
50 % rise in 7 days or less (according to the latest KDIGO
consensus criteria) [12]. Furthermore, our results are
based on studies that were performed in three specific
types of surgery only, i.e. cardiovascular surgery, partial
nephrectomy and liver transplant surgery. Whether the
conclusions can be translated to other types of major sur-
gery is unclear. It is also important to acknowledge that all
included studies were underpowered. Only 473 patients
were included in the meta-analysis for the primary
outcome, and mortality data were only available for
two studies (130 patients). Five of six studies included-Haenszel
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Assessment Tool [14]. The main reasons for this were
a potential imbalance in the number of patients with
pre-existing CKD. Finally, if fenoldopam does indeed
have a beneficial effect on renal function during the
peri-operative period, the optimal duration of therapy
is unknown. In all studies, fenoldopam was adminis-
tered at 0.1 μg/kg/min, but the duration of therapy
varied from the end of surgery to 96 hours post-
operatively.
In summary, there may be a role for fenoldopam in
preventing AKI following high-risk surgery; however,
identification of the patients most likely to benefit and
the optimal dose and duration of therapy remains yet to
be defined. Future well-powered studies should compare
fenoldopam with placebo in a much wider patient group
with normal renal function undergoing high-risk sur-
gery. Moreover the definitions of AKI, and the indica-
tions for RRT, should also be pre-defined and be
consistent with current consensus criteria.
Conclusions
This meta-analysis suggests that peri-operative fenoldo-
pam administration in surgical patients was associated
with a reduction in AKI but there was no effect on RRT
or mortality. Non-standard classification of AKI in the
majority of studies included in this analysis means that
these results should be interpreted with great caution.
Equipoise remains for further adequately powered trials
of fenoldopam in the high-risk surgical population; how-
ever, optimum dose and duration of therapy have yet to
be defined.
Key messages
 Meta-analysis of six randomised controlled trials
showed that peri-operative treatment with fenoldopam
was associated with a significant reduction in acute
kidney injury after major surgery.
 Peri-operative treatment with fenoldopam had no
impact on requirement for renal replacement
therapy or hospital mortality.
 Further research is required to determine the role of
fenoldopam since the studies only included
cardiovascular surgery, partial nephrectomy and
liver transplant surgery, the majority of studies were
at high risk of bias and the criteria for acute kidney
injury varied between studies.
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